Revenio Group Oyj Full Year 2023 Earnings: Beats Expectations

Revenio Group Oyj (HEL:REG1V) Full Year 2023 Results

Key Financial Results

• Revenue: €96.8m (flat on FY 2022).
• Net income: €19.1m (down 12% from FY 2022).
• Profit margin: 20% (down from 22% in FY 2022).
• EPS: €0.72 (down from €0.82 in FY 2022).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Revenio Group Oyj Revenues and Earnings Beat Expectations

Revenue exceeded analyst estimates by 1.4%. Earnings per share (EPS) also surpassed analyst estimates by 2.8%.

In the last 12 months, the only revenue segment was Revenio Health Tech contributing €96.8m. The largest operating expense was General & Administrative costs, amounting to €19.5m (40% of total expenses). Explore how REG1V's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Medical Equipment industry in Finland.

Performance of the Finnish Medical Equipment industry.

The company's shares are down 3.1% from a week ago.

Risk Analysis

Before we wrap up, we've discovered 1 warning sign for Revenio Group Oyj that you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.